Pfizer Inc
PFE25.680USD
-0.590-2.25%
收盤 10/08, 16:00（美東）報價延遲15分鐘
145.99B總市值
13.58本益比TTM
關於 Pfizer Inc 公司
輝瑞公司是一家以研究爲基礎的全球生物製藥公司。該公司在全球範圍內從事生物製藥產品的發現、開發、製造、營銷、銷售和分銷。其生物製藥部門從事以科學爲基礎的生物製藥業務。其生物製藥部門包括輝瑞腫瘤部門、輝瑞美國商業部門和輝瑞國際商業部門。其產品類別包括腫瘤、初級保健和專科護理。其腫瘤產品包括 Ibrance、Xtandi、Inlyta、Bosulif、Lorbrena、Braftovi、Mektovi、Padcev、Adcetris、Talzenna、Tukysa、Elrexfio 和 Tivdak。其初級保健產品包括 Eliquis、Nurtec ODT/Vydura、Comirnaty、Prevnar 家族、Abrysvo、FSME/IMMUN-TicoVac、Paxlovid 和 Lucira by Pfizer。其專科護理產品包括 Xeljanz、Enbrel（美國和加拿大以外）、Inflectra、Cibinqo、Litfulo、Vyndaqel 系列、Genotropin、Sulperazon、Zavicefta、Medrol 和 Panzyga。
Pfizer Inc簡介
公司代碼PFE
公司名稱Pfizer Inc
上市日期Jan 17, 1944
CEODr. Albert Bourla, Ph.D.
員工數量81000
證券類型Ordinary Share
年結日Jan 17
公司地址66 Hudson Boulevard East
城市NEW YORK
上市交易所NYSE Consolidated
國家United States of America
郵編10001-2192
電話12127332323
網址https://www.pfizer.com/
公司代碼PFE
上市日期Jan 17, 1944
CEODr. Albert Bourla, Ph.D.
Pfizer Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
+7800.53%
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
24.85K
+6.62%
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
Eliquis alliance revenues and direct sales
2.00B
13.67%
Vyndaqel family
1.61B
11.02%
Prevnar family
1.38B
9.44%
All other Hospital
1.09B
7.42%
Oncology-Ibrance
1.05B
7.16%
其他
7.52B
51.29%
地區USD
名稱
營收
佔比
United States
8.89B
60.70%
Developed Markets
3.39B
23.16%
Emerging Markets
2.37B
16.15%
業務
地區
業務USD
名稱
營收
佔比
Eliquis alliance revenues and direct sales
2.00B
13.67%
Vyndaqel family
1.61B
11.02%
Prevnar family
1.38B
9.44%
All other Hospital
1.09B
7.42%
Oncology-Ibrance
1.05B
7.16%
其他
7.52B
51.29%
股東統計
更新時間: 8月15日 週五
更新時間: 8月15日 週五
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.33%
State Street Global Advisors (US)
5.21%
BlackRock Institutional Trust Company, N.A.
5.08%
Geode Capital Management, L.L.C.
2.24%
Norges Bank Investment Management (NBIM)
1.65%
其他
76.48%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.33%
State Street Global Advisors (US)
5.21%
BlackRock Institutional Trust Company, N.A.
5.08%
Geode Capital Management, L.L.C.
2.24%
Norges Bank Investment Management (NBIM)
1.65%
其他
76.48%
股東類型
持股股東
佔比
Investment Advisor
32.83%
Investment Advisor/Hedge Fund
22.82%
Research Firm
3.11%
Pension Fund
2.25%
Bank and Trust
1.84%
Sovereign Wealth Fund
1.75%
Hedge Fund
1.27%
Insurance Company
1.24%
Holding Company
0.05%
其他
32.83%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
4787
3.82B
67.19%
-100.74M
2025Q2
4945
3.85B
67.75%
-89.09M
2025Q1
5074
3.86B
67.90%
-51.97M
2024Q4
5153
3.84B
67.74%
-83.26M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.84B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.39M
2023Q4
5089
3.97B
70.25%
-96.67M
2023Q3
4952
4.00B
70.89%
-71.80M
2023Q2
4962
4.02B
71.16%
-62.35M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
530.68M
9.33%
+10.10M
+1.94%
Jun 30, 2025
State Street Global Advisors (US)
296.30M
5.21%
-669.22K
-0.23%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
288.89M
5.08%
-2.65M
-0.91%
Jun 30, 2025
Geode Capital Management, L.L.C.
127.47M
2.24%
+1.82M
+1.45%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
93.65M
1.65%
+5.87M
+6.68%
Jun 30, 2025
Wellington Management Company, LLP
77.00M
1.35%
-26.49M
-25.60%
Jun 30, 2025
MFS Investment Management
72.76M
1.28%
-276.04K
-0.38%
Jun 30, 2025
State Farm Insurance Companies
57.59M
1.01%
-158.70K
-0.27%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
54.65M
0.96%
+4.18M
+8.29%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
49.17M
0.86%
+1.14M
+2.36%
Jun 30, 2025
查看更多
持股ETF
更新時間: 9月2日 週二
更新時間: 9月2日 週二
機構名稱
佔比
Franklin US Dividend Booster Index ETF
128.98%
First Trust NASDAQ Pharmaceuticals ETF
7.17%
First Trust Morningstar Dividend Leaders Index Fund
6.24%
Amplify Weight Loss Drug & Treatment ETF
5.07%
Coastal Compass 100 ETF
4.82%
Invesco Pharmaceuticals ETF
4.82%
WBI Power Factor High Dividend ETF
4.75%
LSV Disciplined Value ETF
4.68%
Vaneck Durable High Dividend ETF
4.38%
iShares U.S. Pharmaceuticals ETF
4.28%
查看更多
Franklin US Dividend Booster Index ETF
佔比128.98%
First Trust NASDAQ Pharmaceuticals ETF
佔比7.17%
First Trust Morningstar Dividend Leaders Index Fund
佔比6.24%
Amplify Weight Loss Drug & Treatment ETF
佔比5.07%
Coastal Compass 100 ETF
佔比4.82%
Invesco Pharmaceuticals ETF
佔比4.82%
WBI Power Factor High Dividend ETF
佔比4.75%
LSV Disciplined Value ETF
佔比4.68%
Vaneck Durable High Dividend ETF
佔比4.38%
iShares U.S. Pharmaceuticals ETF
佔比4.28%
分紅派息
近5年累計派現
44.91B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
Oct 04, 2023
PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Dec 04, 2023
Nov 09, 2023
Jun 22, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Sep 05, 2023 going ex on Jul 27, 2023
Jul 28, 2023
Sep 05, 2023
Jul 27, 2023
Apr 26, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Jun 09, 2023 going ex on May 11, 2023
May 12, 2023
Jun 09, 2023
May 11, 2023
Dec 09, 2022
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Mar 03, 2023 going ex on Jan 26, 2023
Jan 27, 2023
Mar 03, 2023
Jan 26, 2023
Sep 22, 2022
PFE.NB Final Cash Dividend of gross USD 0.4 paid on Dec 05, 2022 going ex on Nov 03, 2022
Nov 04, 2022
Dec 05, 2022
Nov 03, 2022
查看更多
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
